Background: Islet autoantibody detection allows the diagnosis of type 1 diabetes at an early stage, where the patient is still free of symptoms. This allows the prevention of severe complications through education and monitoring and allows initiation of preventative therapies to avoid progression. Fr1da study: The Fr1da study is offered in the context of compulsory preventive medical check-ups for children between the ages of 2 and 5 years. If at least two positive islet autoantibodies are detected in capillary blood, the diagnosis of early stage type 1 diabetes is made. Children and their parents are invited to participate in education sessions to learn about the disease and receive a preventive check-up plan for regular testing of blood and urine glucose, HbA1c, and growth. An anxiety and stress assessment is also performed. Results: Since 2015, over 75,000 children between the ages of 2 and 5 years have been screened for the presence of islet autoantibodies. To date, about 200 children diagnosed with early stage of type 1 diabetes have participated in the education and counselling programme. The psychological assessment revealed no serious distress in any of the families. In addition, no case of ketoacidosis has occurred so far. Conclusion: The Fr1da study has shown that staging for early type 1 diabetes within a public health setting appears to be feasible. The Fr1da study can be easily tranferred to the rest of Germany and is been done since 2016 in Lower Saxony within the framework of the Fr1dolin study.